We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01180868
First Posted: August 12, 2010
Last Update Posted: July 31, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
  Purpose
The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune disease, and inflammation

Condition
Autoimmune Diseases Cancer

Study Type: Observational
Official Title: The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases

Resource links provided by NLM:


Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 1
Study Start Date: May 2008
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
patients with cancer
patients with hematological malignancies and solid tumors
patients with autoimmune dosorders
patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
healthy subjects

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with cancer, patients with autoimmune dosorders, and healthy subjects.
Criteria

Inclusion Criteria:

  • greater than 18 years of age
  • women of childbearing potential will undergo a pregnancy test free of charge
  • patients with hematological malignancies, solid tumors or autoimmune disorders
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01180868


Locations
United States, California
UCLA
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: Christiaan Schiepers, M.D. Ph.D University of California, Los Angeles
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT01180868     History of Changes
Other Study ID Numbers: 08-02-049
DE-PS02-08ER08-01 ( Other Grant/Funding Number: Department of Energy )
CIRM No. RT1-01126-1 ( Other Grant/Funding Number: California Institute for Regenerative Medicine )
First Submitted: August 11, 2010
First Posted: August 12, 2010
Last Update Posted: July 31, 2012
Last Verified: July 2012

Keywords provided by Jonsson Comprehensive Cancer Center:
imaging probe
cancer
inflammatory tissue
inflammatory diseases

Additional relevant MeSH terms:
Autoimmune Diseases
Immune System Diseases